Home › Research › Treatments
Systematic review of atorvastatin for the treatment of Alzheimer's disease
Sun Y, Wang G, Pan Z, Chen S.. Neural regeneration research, 2012-06-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Results Two randomized controlled trials were included, one was scale A, and the other was scale B. The rates of abnormal liver function, withdrawal from treatment, and withdrawal due to adverse effects were higher in the treatment group (OR = 7.86, 95%CI: 2.50-24.69; OR = 4.70, 95%CI: 2.61-8.44; and OR = 5.47, 95%CI: 3.01-9.94; respectively) compared with the placebo group. Efficacy and safety need to be confirmed by larger and higher quality randomized controlled trials, especially for moderate to severe Alzheimer's disease, because results of this systematic review may be limited by selection bias, implementation bias, as well as measurement bias.
What this study adds
Evidence grade: High
This is a pooled review of 710 participants. This review of two trials of atorvastatin found higher rates of abnormal liver function, withdrawal from treatment and withdrawal due to adverse effects in the treatment group than in the placebo group. Reported effect size: OR = 7.86; OR = 4.70; OR = 5.47.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sun, Y., Wang, G., Pan, Z., & Chen, S. (2012). Systematic review of atorvastatin for the treatment of Alzheimer's disease. Neural regeneration research. https://doi.org/10.3969/j.issn.1673-5374.2012.17.010
Vancouver
Sun Y, Wang G, Pan Z, Chen S. Systematic review of atorvastatin for the treatment of Alzheimer's disease. Neural regeneration research. 2012. doi:10.3969/j.issn.1673-5374.2012.17.010. PMID: 25657666.
BibTeX
@article{sun2012-25657666,
author = {Sun, Y. and Wang, G. and Pan, Z. and Chen, S.},
title = {{Systematic review of atorvastatin for the treatment of Alzheimer's disease}},
journal = {Neural regeneration research},
year = {2012},
doi = {10.3969/j.issn.1673-5374.2012.17.010},
pmid = {25657666},
url = {https://doi.org/10.3969/j.issn.1673-5374.2012.17.010}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results Two randomized controlled trials were included, one was scale A, and the other was scale B.
- The rates of abnormal liver function, withdrawal from treatment, and withdrawal due to adverse effects were higher in the treatment group (OR = 7.86, 95%CI: 2.50-24.69; OR = 4.70, 95%CI: 2.61-8.44; and OR = 5.47, 95%CI: 3.01-9.94; respectively) compared with the placebo group.
- Efficacy and safety need to be confirmed by larger and higher quality randomized controlled trials, especially for moderate to severe Alzheimer's disease, because results of this systematic review may be limited by selection bias, implementation bias, as well as measurement bias.
Why it matters
This review of two trials of atorvastatin found higher rates of abnormal liver function, withdrawal from treatment and withdrawal due to adverse effects in the treatment group than in the placebo group. It states that efficacy and safety need confirmation in larger, higher quality trials, so it does not show that atorvastatin treats Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designsystematic review
- Participants710
- Effect sizeOR = 7.86; OR = 4.70; OR = 5.47
- Evidence strengthHigh
How this study scored 53/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. We have no data on journal's citation record, so that was left out: it earned 51 of the 96 points we could judge it on, which is 53 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neural regeneration research) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2012 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 710 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 1 / 7 | Cited 4 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.2 citations a year over 16 year(s) since 2012 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Shuyan Chen: h-index 17 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Shanghai Jiao Tong University: institution h-index 975 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 25657666) |
| Free to read | 2 / 2 | Free to read |
| Points | 51 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 51 of the 96 points we could judge it on is 53 out of 100. |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3969/j.issn.1673-5374.2012.17.010
- PubMed: 25657666
- Original source →
- Free full text: Europe PMC (PubMed Central) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.